Aarti Pharmalabs Ltd Q1 FY27 Earnings Analysis

- The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. - CDMO vertical is expected to grow at a robust 40%-50% next year (FY2027), driving higher value growth. - Xanthine segment aims to achieve around Rs.1,000 Crores revenue in FY2027, showing strong volume and value growth. - API/intermediates segment is expected to surpass FY2025 revenue levels (approx. Rs.700-770 Crores) in FY2027, recovering from previous degrowth due to inventory and price erosion issues. - Ramp-up of new capacities (Atali and Xanthine expansion) to contribute meaningfully to revenues and EBITDA starting from FY2027 Q2 onwards. - Working capital needs may increase due to upfront inventory buildup for large customer projects with no advance payments. - Revenue adjustments due to foreign exchange fluctuations are expected but overall growth trajectory remains positive.

- Revenue growth guidance of 15%-18% CAGR over the next 3-4 years. - EBITDA margin guidance maintained at 15%-18% over the same period. - EBITDA growth expected to materialize meaningfully from Q1 FY2027 onwards as recent capex ramps up, with full contribution taking about a year. - CDMO segment expected to grow 40%-50% in FY2027, driving higher revenue. - Xanthine segment anticipated to reach Rs.1000 Crores revenue in FY2027, surpassing FY2025 levels. - API/intermediates segment expected to recover and surpass FY2025 revenue levels (~Rs.700 Crores). - Capex intensity to reduce from FY2028 as major greenfield projects complete; future expansions to be brownfield, enabling faster ramp-up and better capital efficiency. - EPS growth aligned with revenue and margin expansion, though exact figures not explicitly provided. - Foreign exchange losses excluded from EBITDA guidance.

- Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex. - Capex for dedicated manufacturing block is included but the exact amount is still being finalized. - Atali plant expansion to continue with one new block per year, focusing more on brownfield expansions going forward to reduce capex intensity and speed up ramp-up. - Xanthine derivative capacity to increase from 6,000 to 9,000 metric tons per annum by gradual ramp-up next few quarters. - Steroid and anticancer blocks at Tarapur Unit-4 are undergoing debottlenecking and brownfield expansions in FY2027. - Preliminary design and planning of a dedicated manufacturing block tailored to specific projects; completion expected approximately 12 months after construction begins. - Investment in R&D for peptides and oligonucleotides with long-term potential but no immediate results expected.

- There is no specific mention of any current fundraising through debt or equity in the transcript. - The company has term loans which lead to foreign currency losses, but no new debt fundraising is mentioned. - Capex for dedicated blocks and expansions is being self-funded primarily through cash flows from operations, especially the Xanthine business. - The company is undertaking significant capex (~Rs.400 Crores planned for the current year) mainly from internal accruals rather than raising new external funds. - Future capex is expected to be more brownfield with lower intensity and the balance sheet strength is emphasized as a factor helping in CDMO partnerships. - Rashesh Gogri indicated capex decisions are backed by customer commitments and forward-looking project visibility, suggesting controlled and funded expansion rather than raising fresh capital.

- The company currently has 21 active CDMO customers, a number steady over the last five quarters. - Engagements with these customers are ongoing for newer projects, indicating pipeline development. - In 2025, there was a slowdown in inquiries due to global uncertainties, but the situation has stabilized with increasing inquiries now. - The management mentions having long-term and near-term understandings with customers regarding volumes for new capacities, indicating good visibility on future orders. - Capex decisions for custom-built facilities are based on sensible forecasts from customers. - Large projects tend to have one or two deliveries per year, leading to inventory buildup before delivery. - Customers do not typically provide advance payments, so inventory financing is done by the company. - Overall, the inquiry pipeline is improving compared to the slowdown in the prior year.